☆ 4.7 Article

Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy

Zhe Zhang et al.

Summary: The study identified a drug-tolerant persister (DTP) state in multidrug-resistant (MDR) cancer cells as a tolerance response to combination treatment, partially preventing chemotherapy-induced oxidative stress by promoting vitamin E uptake. The NRF2 transcriptionally regulated NPC1L1 by binding to its promoter, and decreased DNA methylation was also related to this process. Triple-combination therapy with chemotherapeutic agents, verapamil, and ezetimibe demonstrated significant anti-tumor effects and prevented tumor recurrence in mice.

EMBO MOLECULAR MEDICINE (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell et al.

Summary: The development of nanoparticles has shown promising clinical applications, overcoming the limitations of therapeutic interventions and biological barriers. Precision therapies have enhanced treatment efficacy through personalized interventions. Advancements in nanoparticle design aim to optimize drug delivery, improving efficacy in general applications and enabling tailored designs for precision applications.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Review Oncology

Recent Insights into Therapy Resistance in Osteosarcoma

Zachary D. Prudowsky et al.

Summary: Osteosarcoma is the most common bone malignancy of childhood. Standard chemotherapy regimens work well for many patients, but there are minimal options for patients with progressive or resistant disease. A better understanding of therapy resistance is necessary to improve current treatments and design new strategies for future treatment options.

CANCERS (2021)

添加到收藏夹

Review Chemistry, Multidisciplinary

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine-Combination Therapy

Saffiya Habib et al.

Summary: Gemcitabine is a widely used anti-metabolite drug for cancer treatment, but its efficacy is limited by various factors. The use of nanoparticles as delivery agents presents an opportunity to overcome these limitations, improve drug efficacy, and reduce side effects.

NANOMATERIALS (2021)

添加到收藏夹

Article Medicine, General & Internal

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response

Floris Dammeijer et al.

Summary: The study showed that gemcitabine treatment in mesothelioma patients led to an increase in NK cell proliferation and a decrease in T regulatory cell proliferation, along with lower frequencies of MDSCs. Additionally, co-stimulatory molecules such as ICOS, CD28, and HLA-DR were uniformly increased across different types of T cells. Preliminary data also suggested that increased NK cell proliferation and PD-1 expression in T cells following gemcitabine treatment were associated with improved PFS and OS.

EBIOMEDICINE (2021)

添加到收藏夹

Article Nanoscience & Nanotechnology

Anisotropic Truncated Octahedral Au with Pt Deposition on Arris for Localized Surface Plasmon Resonance-Enhanced Photothermal and Photodynamic Therapy of Osteosarcoma

Yeyang Bu et al.

Summary: The use of anisotropic truncated octahedral Au (TOh Au) coated with noble metal Pt enhances the surface plasmonic resonance and photocatalytic effect, providing strong support for cancer treatment.

ACS APPLIED MATERIALS & INTERFACES (2021)

添加到收藏夹

Review Materials Science, Biomaterials

Multifunctional theranostic nanoparticles for biomedical cancer treatments-A comprehensive review

Ganeshlenin Kandasamy et al.

Summary: The modern search for novel agents to treat cancer is driven by historical failures in conventional treatments. Theranostic nanoparticles (TNPs), integrating therapeutic and diagnostic characteristics, have emerged as powerful cancer-treating platforms.

MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2021)

添加到收藏夹

Review Oncology

Advancing therapy for osteosarcoma

Jonathan Gill et al.

Summary: Osteosarcoma, the most common primary bone cancer in children and young adults, presents challenges in treatment due to its rarity and molecular heterogeneity. Collaborative efforts in biological discoveries, technologies, and therapeutic approaches are expected to advance osteosarcoma treatment and improve patient outcomes. The increasing feasibility of molecular profiling, along with the creation of robust model systems and large tissue banks, has enhanced understanding of osteosarcoma biology.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Kynurenine emerges from the shadows-Current knowledge on its fate and function

Marta Marszalek-Grabska et al.

Summary: KYN, a main metabolite of tryptophan produced mainly in the liver by TDO under physiological conditions, is also synthesized by IDO in diseases. While KYN's role in central nervous system pathologies is well studied, its functions in the periphery are less explored.

PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Cell Biology

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway

Fan Luo et al.

Summary: The combination of APG-1252 and gemcitabine exhibits synergistic anticancer activities against nasopharyngeal carcinoma (NPC), providing a promising treatment modality for patients. This combination enhanced NPC cell apoptosis and inhibited invasion, migration, and proliferation both in vitro and in vivo through various mechanisms including caspase-dependent pathways and blocking signaling pathways. Results suggest a potential new therapeutic strategy for advanced NPC.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway

Xueyuan Yang et al.

Summary: The study introduces a composite nanoparticle that can co-deliver a photosensitizer and an IDO inhibitor, showing significantly improved tumor suppression and animal survival in vivo. The treatment increases tumor infiltration of CD8(+) T cells while decreasing the frequencies of MDSCs and Tregs, highlighting the potential for combination therapy.

JOURNAL OF NANOBIOTECHNOLOGY (2021)

添加到收藏夹

Review Oncology

Proteomics, Personalized Medicine and Cancer

Miao Su et al.

Summary: Cancer is a major global public health issue and personalized/precision medicine plays a crucial role in its diagnosis and treatment. Research focuses on cancer biomarkers, the impact of the microbiome, the application of emerging omics technologies, and future prospects.

CANCERS (2021)

添加到收藏夹

Review Cell Biology

The State of Immunotherapy in Hepatobiliary Cancers

Farhan Z. Ilyas et al.

Summary: Hepatobiliary cancers, such as HCC, CCA, and GBC, have limited therapeutic options, but immunotherapy, including immune checkpoint inhibitors and adoptive cell transfer, has shown promise in improving outcomes for these challenging patients.

CELLS (2021)

添加到收藏夹

Article Oncology

IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer

Peng Li et al.

Summary: The study found that IDO1 and PD-L1 were highly expressed in TNBC patients, and Vγ9Vδ2 T cells became exhausted in these patients. Combining Vγ9Vδ2 T cells with IDO1 inhibitor may be applicable for TNBC treatment.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine

Elham Rastegari et al.

Summary: The field of nanomedicine holds promise for efficient and safe delivery of therapeutic compounds, with smart mesoporous silica nanoparticles (MSNs) showing potential for challenging biomedical applications. These MSNs offer advantages such as high loading capacity, site-specific functionalization, and targeted delivery, making them a promising tool for various areas in biomedical research.

PHARMACEUTICS (2021)

添加到收藏夹

Article Immunology

Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C(hi)(gh) Myeloid Cells

Caijun Wu et al.

JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Engineering, Biomedical

Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation

Huiyuan Zhang et al.

BIOMATERIALS (2020)

添加到收藏夹

Article Genetics & Heredity

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Youqiong Ye et al.

GENOME MEDICINE (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone

Shiyao Zhou et al.

JOURNAL OF CONTROLLED RELEASE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Renna Qiu et al.

DRUG DELIVERY (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Zeolite in tissue engineering: Opportunities and challenges

Payam Zarrintaj et al.

MEDCOMM (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death

Canyu Yang et al.

NANOMEDICINE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence

Biagio Ricciuti et al.

PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Review Oncology

Mechanisms of resistance to immune checkpoint inhibitors

Russell W. Jenkins et al.

BRITISH JOURNAL OF CANCER (2018)

添加到收藏夹

Article Chemistry, Multidisciplinary

Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1

Ariel Lewis-Ballester et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)

添加到收藏夹

Review Immunology

Myeloid-derived suppressor cells coming of age

Filippo Veglia et al.

NATURE IMMUNOLOGY (2018)

添加到收藏夹

Review Oncology

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'

George C. Prendergast et al.

TRENDS IN CANCER (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Osteosarcoma: Molecular Pathogenesis and iPSC Modeling

Yu-Hsuan Lin et al.

TRENDS IN MOLECULAR MEDICINE (2017)

添加到收藏夹

Review Oncology

Combination cancer immunotherapies tailored to the tumour microenvironment

Mark J. Smyth et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Emma Eriksson et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Review Medicine, Research & Experimental

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

Douglas Marvel et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Review Medicine, Research & Experimental

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Stefano Ugel et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Oncology

Restoration of defective cross-presentation in tumors by gemcitabine

Alison M. McDonnell et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

Notch Activation as a Driver of Osteogenic Sarcoma

Jianning Tao et al.

CANCER CELL (2014)

添加到收藏夹

Article Oncology

Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway

Z. J. Liao et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2014)

添加到收藏夹

Article Reproductive Biology

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer

Hiroshi Kawaguchi et al.

Journal of Ovarian Research (2014)

添加到收藏夹

Review Oncology

Translational biology of osteosarcoma

Maya Kansara et al.

NATURE REVIEWS CANCER (2014)

添加到收藏夹

Article Immunology

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Rikke B. Holmgaard et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2013)

添加到收藏夹

Review Oncology

Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion

Michael Platten et al.

CANCER RESEARCH (2012)

添加到收藏夹

Article Oncology

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Richard Metz et al.

ONCOIMMUNOLOGY (2012)

添加到收藏夹

Review Immunology

Myeloid-derived suppressor cells as regulators of the immune system

Dmitry I. Gabrilovich et al.

NATURE REVIEWS IMMUNOLOGY (2009)

添加到收藏夹

Article Oncology

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

De-Yan Hou et al.

CANCER RESEARCH (2007)

添加到收藏夹

Review Oncology

Immunosuppressive networks in the tumour environment and their therapeutic relevance

WP Zou

NATURE REVIEWS CANCER (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

AJ Muller et al.

NATURE MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.